Dianne Nunnally Hoppes Laboratory Section of Vascular Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA.
Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Diabetes Care. 2018 Apr;41(4):815-822. doi: 10.2337/dc17-2250. Epub 2018 Jan 31.
Independent association of chronic kidney disease (CKD) and proliferative diabetic retinopathy (PDR) with cardiovascular disease (CVD) has not been established. In the Joslin 50-Year Medalist study, characterizing individuals with type 1 diabetes for 50 years or more, we examined the associations of CKD and PDR with CVD, which was validated by another cohort with type 1 diabetes from Finland.
This cross-sectional study characterized U.S. residents ( = 762) with type 1 diabetes of 50 years or longer (Medalists) at a single site by questionnaire, clinical, ophthalmic, and laboratory studies. A replication cohort ( = 675) from the longitudinal Finnish Diabetic Nephropathy Study (FinnDiane) was used. CKD and PDR were defined as estimated glomerular filtration rate <45 mL/min/1.73 m (CKD stage 3b) and according to the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol, respectively. CVD was based on questionnaires and/or hospital discharge registers. Associations of CVD status with CKD and PDR were analyzed by multivariable logistic regression.
CVD prevalence in the Medalists with CKD and without PDR (+CKD/-PDR) ( = 30) and CVD prevalence in the -CKD/+PDR group ( = 339) were half the prevalence in the +CKD/+PDR group ( = 66) (34.5% and 42.8% vs. 68.2%, = 0.002). PDR status was independently associated with CVD (odds ratio 0.21 [95% CI 0.08-0.58], = 0.003) in patients with CKD. Among the Finnish cohort, a trend toward a lower prevalence of CVD in the +CKD/-PDR group ( = 21) compared with the +CKD/+PDR group ( = 170) (19.1% vs. 37.1%, = 0.10) was also observed.
Absence of PDR in people with type 1 diabetes and CKD was associated with a decreased prevalence of CVD, suggesting that common protective factors for PDR and CVD may exist.
尚未确定慢性肾脏病(CKD)和增生性糖尿病视网膜病变(PDR)与心血管疾病(CVD)的独立关联。在 Joslin 50 年奖章研究中,我们对患有 1 型糖尿病 50 年或更长时间的个体进行了特征描述,该研究使用来自芬兰的另一个 1 型糖尿病队列对 CVD 进行了验证,该队列研究了 CKD 和 PDR 与 CVD 的相关性。
这项横断面研究通过问卷调查、临床、眼科和实验室研究,对美国 1 名患有 50 年或更长时间 1 型糖尿病的居民(=762 人)进行了特征描述。使用来自纵向芬兰糖尿病肾病研究(FinnDiane)的复制队列(=675 人)。CKD 和 PDR 的定义分别为估算肾小球滤过率 <45 mL/min/1.73 m(CKD 3b 期)和根据早期治疗糖尿病视网膜病变研究(ETDRS)协议。CVD 基于问卷和/或住院记录。采用多变量逻辑回归分析 CVD 状态与 CKD 和 PDR 的相关性。
在 CKD 合并无 PDR(+CKD/-PDR)(=30 人)和 CKD 合并 PDR(+CKD/+PDR)(=66 人)中,CVD 的患病率为 34.5%和 42.8%,而在 -CKD/+PDR 组(=339 人)中 CVD 的患病率为 68.2%(=0.002)。在 CKD 患者中,PDR 状态与 CVD 独立相关(比值比 0.21 [95%CI 0.08-0.58],=0.003)。在芬兰队列中,与 +CKD/+PDR 组(=170 人)相比,+CKD/-PDR 组(=21 人)的 CVD 患病率也呈下降趋势(19.1% vs. 37.1%,=0.10)。
1 型糖尿病和 CKD 患者中无 PDR 与 CVD 患病率降低相关,这表明 PDR 和 CVD 的共同保护因素可能存在。